Prof G Markets — Episode Summary

Episode Title: Trump Fires Fed Governor Cook, Eli Lilly’s Weight Loss Pill & How to Not Get Replaced by AI
Hosts: Ed Elson
Date: August 27, 2025
Podcast Network: Vox Media

Episode Overview

This episode of Prof G Markets delivers a rapid breakdown of three major market-moving stories:

• President Trump’s firing attempt of Fed Governor Lisa Cook and its implications for the Federal Reserve’s independence.
• Eli Lilly’s announcement of an oral weight loss medication and its impact on the competitive landscape of GLP-1 drugs.
• The release of a new Stanford study on how generative AI is reshaping youth employment, with Ed Elson offering actionable insights for listeners on how not to be replaced by AI.

Throughout, Ed Elson provides sharp, no-malice market analysis, joined by policy expert Sarah Binder and healthcare research lead Jeff Meacham.

1. Trump’s Attempted Firing of Fed Governor Lisa Cook

Key Segment: 01:48–16:12

What Happened?

• President Trump announced he was firing Fed Governor Lisa Cook over allegations of mortgage fraud, leveraging a "for cause" provision in the Federal Reserve Act.
• Cook rejects the claim and vows to contest her removal, stating the president lacks authority.
• This is an unprecedented move: “No US President has ever tried to oust a sitting Fed governor.” — Ed Elson (04:37)

Legal and Market Analysis

• The Federal Reserve Act allows firing "for cause," but offers no clear definition, leading to legal ambiguity.
  • “The way we generally understand for-cause is that there is a real and indisputable justification for the firing… like misconduct or a breach of policy or some sort of criminal activity.” — Ed Elson (04:59)
• The market’s initial reaction is expectant, with rate cut odds rising and the yield curve widening, but overall sentiment is muted.
  • “It does seem that markets have just sort of shrugged.” — Sarah Binder (09:04)
• Legal consensus: Allegations alone likely do not meet the bar for ‘cause’ without formal charges or judicial review.
  • “How cause is typically then decided, it’s litigated in the courts. It’s a legal process, not a political process.” — Sarah Binder (07:57)

Political and Institutional Impact

• Ed Elson: Suggests the real damage might be signaling to current and future Fed governors: align with the president, or risk removal.
  • “He certainly sent a message to the existing governors and certainly any future governor: if you don’t agree with me, you’re going to be in trouble.” (10:17)
• Sarah Binder warns about the erosion of institutional independence:
  • “He’s made it quite clear that what he wants is a Fed board that’s responsive to his demands for interest rates to be lower, regardless of what the economy demands.” (09:32)
  • “If the Fed is dependent on courts, on Congress, on the markets, and a less aggressive president, then that’s not independence.” (14:21)

Memorable Quote:

“Are you pro-Trump or are you not? Are you MAGA or are you woke? I mean, those are the questions that are beginning to determine interest rates in America and therefore the price of money in America... very dangerous territory.”
— Ed Elson (16:12)

2. Eli Lilly’s Oral Obesity Drug: Orphaglipron

Key Segment: 20:55–27:24

The News

• Eli Lilly announced strong late-stage trial results for Orphaglipron, an oral weight loss drug for people with type 2 diabetes.

• In the trial, patients lost on average 11% of body weight over 72 weeks.

• Unlike Ozempic or Wegovy, this drug is taken as a pill, not an injection.

  • “You literally just take this like you would take a vitamin or you would take an Advil. Huge news for providers, huge news for distributors, and also huge news of course for patients.” — Ed Elson (21:13)

• Result: Eli Lilly stock jumped 6% in a day.

Expert Perspective – Jeff Meacham, Citibank

• Early fears over liver toxicity proved unfounded.

• Weight loss and tolerability “look very compelling” (22:39).

• Orphaglipron stands out vs. Novo Nordisk’s oral Rybelsis:

  • No food effect; patients don’t have to fast.

  • Better scalability on supply.

  • “I would put Lilly at definitely an advantage over Novo among the orals. I’d also say the same thing among injectables as well.” — Jeff Meacham (25:36)

• Market Share:

  • Past: 50–55% Lee, 45–50% Novo.
  • Present: Trending toward 60–65% for Lilly.
  • “Lilly’s done a better job. The oral looks more competitive. So I think that the edge will continue to… will have, continue to have an edge in market share in both diabetes and obesity.” — Jeff Meacham (26:56)

Broader Implications

• Huge potential for market expansion as stigma and inconvenience decline.
• Potential for explosive patient demand:
  • “Taking it as a pill versus injecting it with a needle — that is a huge difference. And that will define the next chapter of the GLP-1 story.” — Ed Elson (28:01)

3. AI & The Job Market: How Not to Be Replaced

Key Segment: 27:24–End (~33:30)

The Stanford Study

• New payroll analysis shows entry-level workers (age 22–25) in AI-exposed roles saw a 13% employment decline since 2022.
• Senior/experienced workers saw jobs remain stable or improve.
• Conclusion:
  • “AI is taking your job — or, to be more specific, it’s not just taking anyone’s job, it’s taking young people’s jobs.” — Ed Elson (28:46)

Prof G’s Advice: The Three “C”s for AI-Proofing Your Career

Drawing from the Prof G Media newsletter, Ed Elson outlines three key skills:

1. Curation

   • In a world of infinite created content, the differentiation is taste and discernment.
   • “You need to find an edge, you need to find a new skill. The best skill we could come up with is curation… your ability to discern what makes a great product versus an okay product.” (29:58)

2. Curiosity

   • Be intellectually omnivorous; new ideas and broad knowledge give you edge.
   • “If you’re the person at work who is down to read for pleasure, who is down to be curious, to ask questions, to learn to use that knowledge, to come up with unique ideas — that gives you an edge, you are probably the one who won’t get replaced by ChatGPT.” (31:48)

3. Connectivity

   • Relationships are irreplaceable; AI can’t network for you.
   • “Your ability to connect with other people and create relationships — that trumps everything else.” (32:30)
   • Real-world examples: Ed and colleagues hired through personal networks.

Memorable Closing Advice:

“If you want to stand out, you need to create relationships. You need to show up face to face, you need to be human. And that’s something AI certainly cannot do.”
— Ed Elson (33:10)

Notable Quotes & Timestamps

• Legal ambiguity of firing Fed governors:

  • “The Federal Reserve act actually doesn’t define it, which isn’t very helpful, but… it means there’s a real and indisputable justification for the firing.”
    — Ed Elson (05:08)

• Danger to Fed independence:

  • “If the Fed is dependent on courts, on Congress, on the markets, and a less aggressive president, then that’s not independence.”
    — Sarah Binder (14:21)

• Lilly’s competitive edge:

  • “There’s no food effect whatsoever. And so there’s no sort of random safety events… Lilly is much better positioned when you think of the oral, you know, what’s coming up next.”
    — Jeff Meacham (24:36)

• AI taking youth jobs:

  • “It is our clearest evidence so far that young people are losing out to AI. This is probably the most important trend for young people to keep track of right now.”
    — Ed Elson (28:59)

Segment Timestamps

• [01:48] — Markets update and Trump fires Fed Governor Cook
• [06:27] — Sarah Binder on the legal and political impact of the firing
• [12:42] — Fed independence: reality and risks
• [20:55] — Eli Lilly’s oral obesity drug announcement and implications
• [22:39] — Jeff Meacham on Orphaglipron vs. competitors
• [27:24] — The AI job market report and “How Not to Get Replaced by AI”
• [32:30] — Prof G’s three skills to future-proof your career

Takeaways

• Fed Independence: The attempted Cook firing casts real doubt on the Federal Reserve’s ability to operate independently, with potentially far-reaching consequences for US monetary policy and markets.
• Obesity Drugs: Eli Lilly's oral GLP-1 drug represents a significant clinical and commercial leap, giving it a tangible edge in the exploding metabolic health market.
• Youth & AI: Entry-level professionals in AI-exposed fields are already experiencing job loss. Adopting skills in curation, curiosity, and connectivity are essential for remaining relevant and resilient in an AI-driven market.

For deeper dives and more resources, listeners are encouraged to visit profgmarkets.com and subscribe to the newsletter for extended insights.